FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783147489> ?p ?o ?g. }

• W2783147489 endingPage "215" @default.
• W2783147489 startingPage "215" @default.
• W2783147489 abstract "<h3>Importance</h3> Nearly half of all patients with heart failure have preserved ejection fraction (HFpEF) as opposed to reduced ejection fraction (HFrEF), yet associations of biomarkers with future heart failure subtype are incompletely understood. <h3>Objective</h3> To evaluate the associations of 12 cardiovascular biomarkers with incident HFpEF vs HFrEF among adults from the general population. <h3>Design, Setting, and Participants</h3> This study included 4 longitudinal community-based cohorts: the Cardiovascular Health Study (1989-1990; 1992-1993 for supplemental African-American cohort), the Framingham Heart Study (1995-1998), the Multi-Ethnic Study of Atherosclerosis (2000-2002), and the Prevention of Renal and Vascular End-stage Disease study (1997-1998). Each cohort had prospective ascertainment of incident HFpEF and HFrEF. Data analysis was performed from June 25, 2015, to November 9, 2017. <h3>Exposures</h3> The following biomarkers were examined: N-terminal pro B-type natriuretic peptide or brain natriuretic peptide, high-sensitivity troponin T or I, C-reactive protein (CRP), urinary albumin to creatinine ratio (UACR), renin to aldosterone ratio, D-dimer, fibrinogen, soluble suppressor of tumorigenicity, galectin-3, cystatin C, plasminogen activator inhibitor 1, and interleukin 6. <h3>Main Outcomes and Measures</h3> Development of incident HFpEF and incident HFrEF. <h3>Results</h3> Among the 22 756 participants in these 4 cohorts (12 087 women and 10 669 men; mean [SD] age, 60 [13] years) in the study, during a median follow-up of 12 years, 633 participants developed incident HFpEF, and 841 developed HFrEF. In models adjusted for clinical risk factors of heart failure, 2 biomarkers were significantly associated with incident HFpEF: UACR (hazard ratio [HR], 1.33; 95% CI, 1.20-1.48;<i>P</i> < .001) and natriuretic peptides (HR, 1.27; 95% CI, 1.16-1.40;<i>P</i> < .001), with suggestive associations for high-sensitivity troponin (HR, 1.11; 95% CI, 1.03-1.19;<i>P</i> = .008), plasminogen activator inhibitor 1 (HR, 1.22; 95% CI, 1.03-1.45;<i>P</i> = .02), and fibrinogen (HR, 1.12; 95% CI, 1.03-1.22;<i>P</i> = .01). By contrast, 6 biomarkers were associated with incident HFrEF: natriuretic peptides (HR, 1.54; 95% CI, 1.41-1.68;<i>P</i> < .001), UACR (HR, 1.21; 95% CI, 1.11-1.32;<i>P</i> < .001), high-sensitivity troponin (HR, 1.37; 95% CI, 1.29-1.46;<i>P</i> < .001), cystatin C (HR, 1.19; 95% CI, 1.11-1.27;<i>P</i> < .001), D-dimer (HR, 1.22; 95% CI, 1.11-1.35;<i>P</i> < .001), and CRP (HR, 1.19; 95% CI, 1.11-1.28;<i>P</i> < .001). When directly compared, natriuretic peptides, high-sensitivity troponin, and CRP were more strongly associated with HFrEF compared with HFpEF. <h3>Conclusions and Relevance</h3> Biomarkers of renal dysfunction, endothelial dysfunction, and inflammation were associated with incident HFrEF. By contrast, only natriuretic peptides and UACR were associated with HFpEF. These findings highlight the need for future studies focused on identifying novel biomarkers of the risk of HFpEF." @default.
• W2783147489 created "2018-01-26" @default.
• W2783147489 creator A5001073189 @default.
• W2783147489 creator A5002821639 @default.
• W2783147489 creator A5004356613 @default.
• W2783147489 creator A5004656494 @default.
• W2783147489 creator A5004882437 @default.
• W2783147489 creator A5005312014 @default.
• W2783147489 creator A5005549802 @default.
• W2783147489 creator A5008531984 @default.
• W2783147489 creator A5010410773 @default.
• W2783147489 creator A5018149893 @default.
• W2783147489 creator A5021361864 @default.
• W2783147489 creator A5023858070 @default.
• W2783147489 creator A5030882947 @default.
• W2783147489 creator A5031658795 @default.
• W2783147489 creator A5033537614 @default.
• W2783147489 creator A5035109163 @default.
• W2783147489 creator A5038689387 @default.
• W2783147489 creator A5039797196 @default.
• W2783147489 creator A5039800294 @default.
• W2783147489 creator A5043064522 @default.
• W2783147489 creator A5050177584 @default.
• W2783147489 creator A5054007340 @default.
• W2783147489 creator A5054561346 @default.
• W2783147489 creator A5056798958 @default.
• W2783147489 creator A5056871200 @default.
• W2783147489 creator A5057910792 @default.
• W2783147489 creator A5064309113 @default.
• W2783147489 creator A5064623534 @default.
• W2783147489 creator A5064977813 @default.
• W2783147489 creator A5070801556 @default.
• W2783147489 creator A5071573513 @default.
• W2783147489 creator A5071844909 @default.
• W2783147489 creator A5074117194 @default.
• W2783147489 creator A5076884619 @default.
• W2783147489 creator A5083447971 @default.
• W2783147489 creator A5085451281 @default.
• W2783147489 date "2018-03-01" @default.
• W2783147489 modified "2023-10-11" @default.
• W2783147489 title "Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction" @default.
• W2783147489 cites W129855031 @default.
• W2783147489 cites W1568121239 @default.
• W2783147489 cites W164205712 @default.
• W2783147489 cites W1976196376 @default.
• W2783147489 cites W2001890682 @default.
• W2783147489 cites W2011819931 @default.
• W2783147489 cites W2038636008 @default.
• W2783147489 cites W2048178709 @default.
• W2783147489 cites W2062608369 @default.
• W2783147489 cites W2073023604 @default.
• W2783147489 cites W2081311610 @default.
• W2783147489 cites W2086291738 @default.
• W2783147489 cites W2093063170 @default.
• W2783147489 cites W2098898523 @default.
• W2783147489 cites W210033350 @default.
• W2783147489 cites W2106421416 @default.
• W2783147489 cites W2109348687 @default.
• W2783147489 cites W2113538868 @default.
• W2783147489 cites W2115350032 @default.
• W2783147489 cites W2122465146 @default.
• W2783147489 cites W2123831918 @default.
• W2783147489 cites W2137625135 @default.
• W2783147489 cites W2137724408 @default.
• W2783147489 cites W2140016310 @default.
• W2783147489 cites W2146070412 @default.
• W2783147489 cites W2146571866 @default.
• W2783147489 cites W2151474448 @default.
• W2783147489 cites W2152865365 @default.
• W2783147489 cites W2156097706 @default.
• W2783147489 cites W2159346037 @default.
• W2783147489 cites W2163917890 @default.
• W2783147489 cites W2211287272 @default.
• W2783147489 cites W2256871273 @default.
• W2783147489 cites W2342308986 @default.
• W2783147489 cites W2532574047 @default.
• W2783147489 cites W2548165040 @default.
• W2783147489 cites W2556053991 @default.
• W2783147489 cites W2556477461 @default.
• W2783147489 cites W2556674574 @default.
• W2783147489 cites W2623867926 @default.
• W2783147489 cites W2886689397 @default.
• W2783147489 cites W57547456 @default.
• W2783147489 doi "https://doi.org/10.1001/jamacardio.2017.4987" @default.
• W2783147489 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5862778" @default.
• W2783147489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29322198" @default.
• W2783147489 hasPublicationYear "2018" @default.
• W2783147489 type Work @default.
• W2783147489 sameAs 2783147489 @default.
• W2783147489 citedByCount "162" @default.
• W2783147489 countsByYear W27831474892018 @default.
• W2783147489 countsByYear W27831474892019 @default.
• W2783147489 countsByYear W27831474892020 @default.
• W2783147489 countsByYear W27831474892021 @default.
• W2783147489 countsByYear W27831474892022 @default.
• W2783147489 countsByYear W27831474892023 @default.
• W2783147489 crossrefType "journal-article" @default.
• W2783147489 hasAuthorship W2783147489A5001073189 @default.

• next